---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211935"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:00:44.446014+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement

## Summary
- Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.
- Cash of $117.2M as of March 31; April private placement raised $30M, extending runway into Q1 2028.
- Phase 2b ADAPTIVE trial in AD advancing under amended protocol; topline data anticipated Q4 2027.
- Plan to initiate Phase 2 in alopecia areata in 2026; initial data expected 2028, based on proof-of-concept.

## SEC filing metadata
- accession: 0001193125-26-211935
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/0001193125-26-211935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/d151394d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211935
- JSON: https://secwatch.observer/filing/0001193125-26-211935.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.